🛡️ Comprehensive Immunity Guide (by Didactic Med)

Evidence-Based Clinical Immunology for Healthcare Professionals

🎯 Introduction to the Immune System

Definition: The immune system is a complex network of cells, tissues, organs, and molecules that work together to defend the body against infectious agents, eliminate damaged cells, and recognize self from non-self antigens.

🔑 Key Functions of the Immune System

🛡️ Protection

  • Defense against pathogens (bacteria, viruses, fungi, parasites)
  • Elimination of infected or damaged cells
  • Tumor surveillance and destruction

🎯 Recognition

  • Distinguish self from non-self antigens
  • Pattern recognition receptors (PRRs)
  • Antigen presentation mechanisms

💾 Memory

  • Immunological memory formation
  • Enhanced secondary responses
  • Long-term protection

⚖️ Regulation

  • Self-tolerance maintenance
  • Prevention of autoimmunity
  • Resolution of inflammation

🏛️ Primary Lymphoid Organs

Organ Location Function Key Features
Bone Marrow Long bones, vertebrae, pelvis B-cell maturation, hematopoiesis Site of all blood cell production
Thymus Anterior mediastinum T-cell maturation and selection Involutes with age, most active in childhood

🌐 Secondary Lymphoid Organs

Organ Function Clinical Significance
Spleen Blood filtration, immune surveillance, antibody production Asplenia increases risk of encapsulated bacteria infections
Lymph Nodes Filter lymph, antigen presentation, lymphocyte activation Lymphadenopathy indicates infection or malignancy
MALT (Mucosa-Associated Lymphoid Tissue) Mucosal immunity, IgA production First line defense at mucosal surfaces
Tonsils & Adenoids Pharyngeal immune defense Common site of childhood infections

🔬 Cellular Components

Major Immune Cell Types:

  • Neutrophils: 50-70% of WBCs, first responders, phagocytosis
  • Lymphocytes: 20-40% of WBCs (T cells, B cells, NK cells)
  • Monocytes/Macrophages: 2-10% of WBCs, phagocytosis, antigen presentation
  • Eosinophils: 1-4% of WBCs, parasitic infections, allergic responses
  • Basophils/Mast Cells: <1% of WBCs, allergic reactions, histamine release
  • Dendritic Cells: Professional antigen-presenting cells, bridge innate and adaptive immunity

🧬 Molecular Components

Antibodies (Immunoglobulins)

Type % Total Location Function
IgG 75-80% Blood, tissue fluids Secondary immune response, crosses placenta, complement activation
IgA 10-15% Mucosal surfaces, secretions Mucosal immunity, prevents pathogen adhesion
IgM 5-10% Blood Primary immune response, efficient complement activator
IgE <0.01% Tissue, bound to mast cells Allergic reactions, parasitic infections
IgD <1% B-cell surface B-cell receptor, unclear biological function

Complement System

Three Activation Pathways:

  • Classical Pathway - Antibody-antigen complexes (C1q, C1r, C1s)
  • Alternative Pathway - Spontaneous activation on pathogen surfaces (Factor B, Factor D)
  • Lectin Pathway - Mannose-binding lectin (MBL) recognition

All converge at C3 convertase → C5 convertase → Membrane Attack Complex (MAC)

Functions of Complement

  • Opsonization (C3b)
  • Chemotaxis (C5a)
  • Direct cell lysis (MAC: C5b-9)
  • Immune complex clearance
  • Enhanced antibody responses

Clinical Significance

  • C3 deficiency: severe recurrent infections
  • C1 inhibitor deficiency: hereditary angioedema
  • C5-C9 deficiency: Neisseria infections
  • Complement dysregulation: PNH, aHUS

⚡ Innate Immunity: First Line of Defense

Characteristics:
  • Non-specific, rapid response (minutes to hours)
  • No memory formation
  • Germline-encoded receptors
  • Recognizes pathogen-associated molecular patterns (PAMPs)
  • Evolutionarily conserved

🧱 Physical and Chemical Barriers

Barrier Mechanism Clinical Relevance
Skin Physical barrier, low pH, sebum, antimicrobial peptides Burns increase infection risk
Mucous Membranes Mucus trapping, ciliary clearance, IgA secretion Primary ciliary dyskinesia → recurrent infections
Gastric Acid pH 1.5-3.5, kills most pathogens PPI use increases GI infections
Normal Flora Competitive exclusion, antimicrobial production Antibiotic use → C. difficile overgrowth
Lysozyme Cleaves bacterial cell walls Present in tears, saliva, mucus

🎯 Pattern Recognition Receptors (PRRs)

Toll-Like Receptors (TLRs) ▼
TLR Location Ligand (PAMP) Pathogen
TLR-1/2/6 Cell surface Lipoproteins, peptidoglycan Gram-positive bacteria, mycobacteria
TLR-3 Endosome dsRNA Viruses
TLR-4 Cell surface LPS Gram-negative bacteria
TLR-5 Cell surface Flagellin Flagellated bacteria
TLR-7/8 Endosome ssRNA RNA viruses
TLR-9 Endosome CpG DNA Bacteria, DNA viruses
Clinical Application: TLR agonists are used as vaccine adjuvants (e.g., MPL in HPV vaccine uses TLR-4)
NOD-Like Receptors (NLRs) ▼

Cytoplasmic sensors of intracellular pathogens and danger signals

  • NOD1/NOD2: Bacterial peptidoglycan recognition
    • Mutations: Crohn's disease susceptibility (NOD2)
    • Activate NF-κB pathway
  • NLRP3 Inflammasome:
    • Detects cellular stress, crystals, pore-forming toxins
    • Activates caspase-1 → IL-1β and IL-18 maturation
    • Dysregulation: autoinflammatory diseases (CAPS)
RIG-I-Like Receptors (RLRs) ▼

Cytoplasmic viral RNA sensors

  • RIG-I: Short dsRNA, 5' triphosphate RNA
  • MDA5: Long dsRNA
  • Both activate IRF3/IRF7 → Type I IFN production
C-Type Lectin Receptors (CLRs) ▼

Recognize carbohydrate structures on pathogens

  • Dectin-1: β-glucan on fungal cell walls
  • DC-SIGN: Mannose-containing glycans (HIV, TB)
  • Mannose Receptor: Bacterial and fungal mannose

🔥 Cellular Components of Innate Immunity

Neutrophils

Characteristics

  • Most abundant leukocytes (50-70%)
  • Short lifespan (6-8 hours in circulation)
  • First responders to infection
  • Multilobed nucleus (3-5 lobes)

Functions

  • Phagocytosis and intracellular killing
  • Degranulation (antimicrobial proteins)
  • NET formation (chromatin traps)
  • ROS production (respiratory burst)
Clinical Correlations:
  • Neutropenia: ANC <1500/μL, severe <500/μL → high infection risk
  • Chronic Granulomatous Disease: Defective NADPH oxidase → impaired ROS production → catalase-positive infections (S. aureus, Aspergillus)
  • Leukocyte Adhesion Deficiency: Defective β2-integrin → impaired neutrophil migration → delayed umbilical cord separation, recurrent infections

Macrophages

Tissue-Resident Macrophages:

  • Kupffer cells: Liver
  • Alveolar macrophages: Lungs
  • Microglia: Central nervous system
  • Osteoclasts: Bone
  • Histiocytes: Connective tissue

Macrophage Polarization

Type Activation Signals Function Cytokine Production
M1 (Classical) IFN-γ, LPS, TNF-α Pro-inflammatory, antimicrobial, tumor killing IL-12, TNF-α, IL-1β, IL-6, ROS
M2 (Alternative) IL-4, IL-13, IL-10 Anti-inflammatory, tissue repair, wound healing IL-10, TGF-β, arginase

Natural Killer (NK) Cells

Recognition Mechanisms:

Balance of Inhibitory and Activating Signals

  • Inhibitory Receptors: KIR (Killer Immunoglobulin-like Receptors) recognize MHC class I
    • Normal cells express MHC-I → inhibitory signal → no killing
    • Infected/tumor cells downregulate MHC-I → loss of inhibition → killing
  • Activating Receptors: NKG2D, NCRs recognize stress-induced ligands
  • ADCC (Antibody-Dependent Cell-mediated Cytotoxicity): CD16 (FcγRIII) binds antibody-coated targets

Killing Mechanisms

  • Perforin/Granzyme: Pore formation → apoptosis
  • FasL-Fas: Death receptor pathway
  • TRAIL: Tumor necrosis factor-related apoptosis

Cytokine Production

  • IFN-γ: Macrophage activation, antiviral
  • TNF-α: Pro-inflammatory
  • GM-CSF: Granulocyte development
Clinical Significance:
  • NK cell deficiency: Severe herpesvirus infections (EBV, CMV, HSV)
  • Tumor surveillance: NK cells eliminate transformed cells
  • Therapeutic targets: CAR-NK cells, checkpoint inhibitors

Dendritic Cells (DCs)

Professional Antigen-Presenting Cells - Bridge between Innate and Adaptive Immunity

Key Functions:

  • Antigen capture: Immature DCs in peripheral tissues
  • Migration: To lymph nodes via CCR7
  • Maturation: Upregulate MHC-II, costimulatory molecules (CD80/CD86)
  • T cell activation: Three-signal model
    1. MHC-peptide complex → TCR
    2. CD80/CD86 → CD28 (costimulation)
    3. Cytokines (IL-12, IFN-α/β) → differentiation

DC Subsets:

  • Conventional DCs (cDC1, cDC2): Classical antigen presentation
  • Plasmacytoid DCs (pDCs): Major IFN-I producers in viral infections
  • Langerhans cells: Skin-resident DCs

💥 Inflammatory Response

Cardinal Signs of Inflammation

🔴 Rubor (Redness)

Vasodilation and increased blood flow

🌡️ Calor (Heat)

Increased metabolic activity and blood flow

⬆️ Tumor (Swelling)

Vascular permeability and edema

⚡ Dolor (Pain)

Nociceptor stimulation by mediators

Key Inflammatory Mediators

Mediator Source Primary Effects Clinical Application
Histamine Mast cells, basophils Vasodilation, vascular permeability, pain Antihistamines for allergic reactions
Prostaglandins COX pathway Pain, fever, vasodilation NSAIDs (COX inhibitors)
Leukotrienes 5-LOX pathway Bronchoconstriction, vascular permeability Leukotriene inhibitors (asthma)
TNF-α Macrophages Fever, acute phase proteins, cachexia Anti-TNF therapy (autoimmune diseases)
IL-1β Macrophages, inflammasome Fever, acute phase response IL-1 antagonists (autoinflammatory diseases)
IL-6 Macrophages, T cells Acute phase proteins, fever, B-cell stimulation Tocilizumab (IL-6 receptor blockade)
Bradykinin Kinin system Pain, vasodilation, vascular permeability Implicated in ACE-I induced angioedema

Acute Phase Response

Positive Acute Phase Proteins (↑ in inflammation):

  • C-Reactive Protein (CRP): Opsonization, complement activation - Most sensitive marker
  • Serum Amyloid A (SAA): Can lead to AA amyloidosis in chronic inflammation
  • Fibrinogen: Coagulation, ↑ ESR
  • Haptoglobin: Binds free hemoglobin
  • Ferritin: Iron sequestration (anemia of inflammation)
  • Complement factors: C3, C4

Negative Acute Phase Proteins (↓ in inflammation):

  • Albumin: Negative acute phase reactant
  • Transferrin: Iron transport

🎓 Adaptive Immunity: Specific and Memory-Based Defense

Key Characteristics:

  • Specificity: Recognizes unique antigens
  • Memory: Enhanced response upon re-exposure
  • Diversity: >10^11 different antigen receptors
  • Self-tolerance: Distinguishes self from non-self
  • Delayed response: Days to weeks for primary response

⚖️ Comparison: Innate vs Adaptive Immunity

Feature Innate Immunity Adaptive Immunity
Response Time Minutes to hours Days to weeks (primary), hours to days (secondary)
Specificity Pattern-based (PAMPs) Antigen-specific
Memory None Immunological memory
Receptors Germline-encoded (PRRs) Somatically recombined (TCR, BCR)
Key Cells Neutrophils, macrophages, NK cells T cells, B cells

🧬 T Lymphocytes (T Cells)

T Cell Development in the Thymus

Stages of T Cell Maturation ▼
  1. Bone marrow origin: T cell precursors migrate to thymus
  2. Double-negative (DN) stage: CD4⁻ CD8⁻ thymocytes
    • TCR β-chain rearrangement
    • β-selection checkpoint
  3. Double-positive (DP) stage: CD4⁺ CD8⁺ thymocytes
    • TCR α-chain rearrangement
    • Complete TCR αβ expression
  4. Positive selection: (Thymic cortex)
    • Tests for MHC restriction
    • Cells that recognize self-MHC survive
    • Failure → apoptosis (95% die)
  5. Negative selection: (Thymic medulla)
    • Tests for self-reactivity
    • Cells that strongly recognize self-antigens → apoptosis
    • AIRE (Autoimmune Regulator) expresses tissue-specific antigens
    • AIRE mutations → APECED syndrome (autoimmune polyendocrinopathy)
  6. Single-positive (SP) stage: CD4⁺ or CD8⁺
    • MHC-II recognition → CD4⁺ (helper T cells)
    • MHC-I recognition → CD8⁺ (cytotoxic T cells)
Result: Only 1-2% of thymocytes survive to become mature, self-tolerant T cells

Major T Cell Subsets

Subset Surface Markers MHC Restriction Primary Functions Key Cytokines
CD4⁺ Helper T cells CD4⁺, CD3⁺, TCR MHC class II Help B cells, activate macrophages, orchestrate immune response Subset-dependent
CD8⁺ Cytotoxic T cells CD8⁺, CD3⁺, TCR MHC class I Kill infected cells, tumor cells IFN-γ, TNF-α, perforin, granzymes
Regulatory T cells (Tregs) CD4⁺, CD25⁺, FoxP3⁺ MHC class II Maintain self-tolerance, suppress excessive immune responses IL-10, TGF-β
γδ T cells TCR γδ Non-MHC restricted Mucosal immunity, recognize lipid antigens IFN-γ, IL-17

CD4⁺ Helper T Cell Subsets

Subset Inducing Cytokines Master Transcription Factor Signature Cytokines Functions Diseases
Th1 IL-12, IFN-γ T-bet IFN-γ, IL-2, TNF-β Intracellular pathogens, activate macrophages, cell-mediated immunity Excessive: Type 1 diabetes, MS, IBD
Th2 IL-4 GATA-3 IL-4, IL-5, IL-13 Parasitic infections, allergy, IgE production, eosinophil activation Excessive: Asthma, allergies, atopy
Th17 TGF-β + IL-6, IL-23 RORγt IL-17A/F, IL-22 Extracellular bacteria/fungi, neutrophil recruitment, mucosal immunity Excessive: Psoriasis, RA, IBD
Tfh (Follicular Helper) IL-6, IL-21 Bcl-6 IL-21, IL-4 B cell help, germinal center formation, antibody class switching Dysregulation: Autoimmune diseases
Treg TGF-β, IL-2 FoxP3 IL-10, TGF-β, IL-35 Immune suppression, maintain tolerance Deficiency: IPEX syndrome, autoimmunity

Clinical Significance of Th1/Th2 Balance:

  • Leprosy spectrum:
    • Tuberculoid leprosy: Th1-dominant response (cell-mediated, limited disease)
    • Lepromatous leprosy: Th2-dominant response (antibody-mediated, disseminated disease)
  • Pregnancy: Th2 shift protects fetus (foreign antigens) from maternal Th1 rejection
  • Allergic diseases: Excessive Th2 responses
  • Therapeutic targeting: Biologics target specific cytokines (anti-IL-4, anti-IL-5, anti-IL-17)

CD8⁺ Cytotoxic T Lymphocytes (CTLs)

Activation Requirements

  1. Signal 1: TCR recognition of MHC-I + peptide
  2. Signal 2: Costimulation (CD28-CD80/86)
  3. Signal 3: Cytokines (IL-12, IFN-α/β)
  4. CD4⁺ help: Often required for optimal response

Killing Mechanisms

  • Perforin/Granzyme pathway:
    • Perforin creates pores
    • Granzymes enter → activate caspases → apoptosis
  • Fas-FasL pathway: Death receptor-mediated apoptosis
  • Cytokine secretion: TNF-α, IFN-γ
Clinical Applications:
  • Viral immunity: CTLs critical for clearing viral infections
  • Tumor immunity: Recognize tumor-associated antigens
  • Transplant rejection: Alloreactive CTLs attack donor tissue
  • CAR-T therapy: Engineered CD8⁺ T cells target cancer
  • Checkpoint inhibitors: Block PD-1/CTLA-4 to enhance CTL function

🅱️ B Lymphocytes and Humoral Immunity

B Cell Development

Stages of B Cell Maturation ▼

Bone Marrow (Antigen-Independent):

  1. Pro-B cell:
    • Heavy chain (IgH) rearrangement begins (D-J joining)
    • Requires IL-7
  2. Pre-B cell:
    • Complete heavy chain rearrangement (V-DJ joining)
    • Pre-BCR formation (μ heavy chain + surrogate light chain)
    • Pre-BCR signaling → proliferation, allelic exclusion
  3. Immature B cell:
    • Light chain rearrangement (κ or λ)
    • Surface IgM expression
    • Central tolerance: Self-reactive B cells undergo:
      • Receptor editing (try new light chain)
      • Anergy (functional unresponsiveness)
      • Apoptosis (clonal deletion)
  4. Mature naive B cell:
    • Co-express IgM and IgD
    • Exit to periphery

Peripheral Lymphoid Organs (Antigen-Dependent):

  • Activation: Antigen recognition + T cell help (or T-independent)
  • Germinal center reaction:
    • Somatic hypermutation (affinity maturation)
    • Class switch recombination
    • Selection for high-affinity clones
  • Differentiation: Plasma cells or memory B cells

B Cell Activation Pathways

Type Antigens T Cell Help Required Response Examples
T-Dependent Protein antigens Yes (Tfh cells) High-affinity IgG, class switching, memory, germinal centers Most viral and bacterial proteins, vaccines
T-Independent Type 1 (TI-1) Polyclonal activators No Low-affinity IgM, no memory LPS (endotoxin)
T-Independent Type 2 (TI-2) Repetitive polysaccharides No Low-affinity IgM/IgG2, limited memory Bacterial capsules (pneumococcus, meningococcus)
Clinical Significance:
  • Children <2 years: Poor response to T-independent antigens (immature immune system) → pneumococcal conjugate vaccine (converts to T-dependent)
  • Asplenia: Impaired response to T-independent antigens → risk of encapsulated bacteria
  • CVID (Common Variable Immunodeficiency): Impaired T-dependent responses → recurrent sinopulmonary infections

Antibody Class Switching

Mechanism: Irreversible DNA recombination changes constant region while preserving variable region (antigen specificity maintained)

Signals Required:

  • CD40L (from T cells) binding to CD40 (on B cells)
  • Cytokines determine which class (IgG, IgA, or IgE)
Target Isotype Cytokine Signal Function
IgG IFN-γ (Th1) Opsonization, complement fixation, ADCC, crosses placenta
IgA TGF-β, IL-5, IL-10 Mucosal immunity, secretory antibody
IgE IL-4, IL-13 (Th2) Mast cell/basophil activation, parasitic immunity, allergies
Hyper-IgM Syndromes: Defective class switching
  • X-linked Hyper-IgM (CD40L deficiency): Boys, recurrent infections, opportunistic infections (Pneumocystis)
  • Autosomal Hyper-IgM (AID deficiency): Defective somatic hypermutation and class switching
  • Lab findings: High IgM, very low/absent IgG, IgA, IgE
  • Treatment: IVIG, prophylactic antibiotics, HSCT

Antibody Functions

Direct Effects

  • Neutralization: Block pathogen binding to host cells
  • Agglutination: Clump pathogens for easier phagocytosis
  • Precipitation: Cross-link soluble antigens

Fc-Mediated Effects

  • Opsonization: Enhance phagocytosis (FcR binding)
  • ADCC: NK cells kill antibody-coated targets
  • Complement activation: Classical pathway initiation
  • Neonatal immunity: IgG crosses placenta (FcRn)

🧠 Immunological Memory

Characteristics of Memory Response:

  • Faster: Hours to days vs. days to weeks
  • Stronger: Higher magnitude response
  • More specific: Higher affinity antibodies (affinity maturation)
  • More sustained: Long-lived plasma cells and memory cells
  • Lower threshold: Requires less antigen for activation

Primary vs Secondary Immune Response

Feature Primary Response Secondary Response
Lag Phase 5-10 days 1-3 days
Peak Response Day 10-17 Day 3-5
Antibody Level Lower 10-100x higher
Predominant Antibody IgM, then IgG IgG (or other switched isotype)
Affinity Lower Higher (affinity maturation)
Duration Weeks to months Years to lifetime

Types of Memory Cells

Memory B Cells

  • Express high-affinity, class-switched BCR
  • Long-lived (years to decades)
  • Rapidly differentiate into plasma cells upon re-exposure
  • Require lower antigen dose for activation

Long-Lived Plasma Cells

  • Reside in bone marrow
  • Continuously secrete antibodies
  • Provide baseline humoral immunity
  • Can persist for lifetime

Memory T Cells

  • Central memory (Tcm): Lymph nodes, high proliferative capacity
  • Effector memory (Tem): Peripheral tissues, rapid effector functions
  • Tissue-resident memory (Trm): Remain in tissues, rapid local response

Maintenance Mechanisms

  • Low-level antigen persistence
  • Cross-reactive antigens
  • Homeostatic proliferation (IL-7, IL-15)
  • Independent of thymus (after childhood)

Clinical Applications:

  • Vaccination strategy: Prime (initial vaccine) → Boost (subsequent doses) to establish robust memory
  • Natural infection: Usually provides stronger, longer-lasting memory than vaccination
  • Waning immunity: Some vaccines require boosters (tetanus q10 years, pertussis)
  • Serology: IgM suggests acute/recent infection; IgG suggests past infection or vaccination
  • Immunological memory failure: Some pathogens evade memory (malaria, HIV) through antigenic variation

🔴 Immunodeficiency Disorders

Key Clinical Features Suggesting Immunodeficiency:

  • ≥8 new ear infections within 1 year
  • ≥2 serious sinus infections within 1 year
  • ≥2 months on antibiotics with little effect
  • ≥2 pneumonias within 1 year
  • Failure to thrive in infancy
  • Recurrent deep skin/organ abscesses
  • Persistent thrush or skin fungal infections
  • Need for IV antibiotics to clear infections
  • ≥2 deep-seated infections (meningitis, osteomyelitis, sepsis)
  • Family history of primary immunodeficiency

Primary Immunodeficiencies

Combined T and B Cell Defects ▼

Severe Combined Immunodeficiency (SCID)

Most severe primary immunodeficiency - "Bubble Boy Disease"

Pathophysiology: Defective T cell development → no T cell help → defective B cell function

Genetics: Multiple genetic defects

  • X-linked SCID (50-60%): IL2RG (common γ chain) defect
    • Affects IL-2, IL-4, IL-7, IL-9, IL-15, IL-21 receptors
    • T⁻B⁺NK⁻ phenotype
  • ADA deficiency (15%): Toxic metabolite accumulation
    • T⁻B⁻NK⁻ phenotype
    • Enzyme replacement available
  • RAG1/RAG2 deficiency: Cannot perform V(D)J recombination
    • T⁻B⁻NK⁺ phenotype

Clinical Presentation:

  • Present at 3-6 months (maternal IgG wanes)
  • Severe recurrent infections (bacterial, viral, fungal, opportunistic)
  • Chronic diarrhea, failure to thrive
  • Absent lymphoid tissue (no tonsils, small lymph nodes)
  • Persistent thrush
  • GVHD from maternal T cells or blood transfusions

Laboratory:

  • Severe lymphopenia (<2000/μL)
  • Absent/very low T cells
  • Hypogammaglobulinemia
  • Absent thymic shadow on CXR

Treatment:

  • Hematopoietic Stem Cell Transplantation (HSCT) - curative
  • Gene therapy (ADA-SCID, X-linked SCID)
  • IVIG, prophylactic antibiotics until transplant
  • AVOID: Live vaccines, blood transfusions (unless irradiated)

DiGeorge Syndrome (22q11.2 Deletion)

Pathophysiology: Thymic hypoplasia → impaired T cell development

Clinical Features - CATCH-22:

  • Cardiac defects (Tetralogy of Fallot, VSD)
  • Abnormal facies (low-set ears, micrognathia, hypertelorism)
  • Thymic hypoplasia/aplasia
  • Cleft palate
  • Hypocalcemia (parathyroid hypoplasia)
  • 22 - chromosome 22q11.2 deletion

Immunologic Findings:

  • Variable T cell deficiency (usually partial)
  • Normal B cell numbers, may have impaired antibody responses
  • Increased infections in infancy, often improves with age

Treatment:

  • Usually supportive (most have partial function)
  • Severe cases: thymic transplantation
  • Calcium/vitamin D supplementation
  • Cardiac surgery as needed
B Cell/Antibody Deficiencies ▼

X-Linked Agammaglobulinemia (XLA/Bruton's)

Genetics BTK (Bruton's tyrosine kinase) mutation - X-linked recessive
Pathophysiology Block in B cell maturation at pre-B cell stage → no mature B cells
Clinical Features
  • Boys, present after 6 months (maternal IgG wanes)
  • Recurrent sinopulmonary infections (encapsulated bacteria)
  • Absent tonsils and lymph nodes
  • No B cells in circulation
  • Susceptible to enteroviral infections (chronic meningoencephalitis)
Laboratory
  • All Ig isotypes severely decreased (<100 mg/dL)
  • CD19⁺ B cells <2%
  • Normal T cells
Treatment Lifelong IVIG (400-600 mg/kg q3-4 weeks) or SCIG

Common Variable Immunodeficiency (CVID)

Most common symptomatic primary immunodeficiency (after IgA deficiency)

Pathophysiology: Heterogeneous - impaired B cell differentiation/function, defective T cell help

Clinical Features:

  • Usually presents in 2nd-4th decade (can be earlier)
  • Recurrent sinopulmonary infections
  • Bronchiectasis, chronic lung disease
  • Autoimmune diseases (30%): ITP, autoimmune hemolytic anemia, RA
  • Granulomatous disease (lung, liver, spleen)
  • Lymphoproliferative disease, lymphoma risk
  • Chronic diarrhea (Giardia, nodular lymphoid hyperplasia)

Laboratory:

  • IgG <400 mg/dL + low IgA and/or IgM
  • Poor vaccine responses
  • Normal/low B cell numbers
  • May have T cell defects

Treatment:

  • IVIG or SCIG replacement
  • Prophylactic antibiotics if needed
  • Treat autoimmune/inflammatory complications
  • Regular monitoring for malignancy

Selective IgA Deficiency

Most common primary immunodeficiency (1:300-700)

Definition: IgA <7 mg/dL with normal IgG and IgM

Clinical Presentation:

  • Often asymptomatic (most individuals)
  • Recurrent sinopulmonary infections
  • GI infections (Giardia)
  • Allergies, atopy, asthma
  • Autoimmune diseases (celiac, SLE, RA)

Complications:

  • Anti-IgA antibodies: Risk of anaphylaxis with blood products or IVIG
    • Use washed RBCs if transfusion needed
    • IgA-depleted IVIG if Ig replacement needed
  • May progress to CVID (rare)

Treatment:

  • Usually no treatment needed
  • Antibiotics for infections as needed
  • Avoid IVIG (unless IgA-depleted preparation)
Phagocyte Defects ▼

Chronic Granulomatous Disease (CGD)

Genetics NADPH oxidase defects (X-linked 60%, autosomal recessive 40%)
Pathophysiology Defective respiratory burst → cannot kill catalase-positive organisms
Clinical Features
  • Recurrent infections with catalase-positive organisms:
    • Bacteria: S. aureus, Burkholderia cepacia, Serratia, Nocardia
    • Fungi: Aspergillus (most common cause of death)
  • Granuloma formation (lung, liver, GI tract, GU tract)
  • Lymphadenitis, hepatosplenomegaly
  • Inflammatory bowel disease-like symptoms
Diagnosis
  • Nitroblue tetrazolium (NBT) test: Negative (fails to reduce dye)
  • Dihydrorhodamine (DHR) flow cytometry: Gold standard, more sensitive
Treatment
  • Prophylactic TMP-SMX
  • Prophylactic itraconazole
  • IFN-γ (reduces infection frequency)
  • Aggressive treatment of infections
  • HSCT (curative)

Leukocyte Adhesion Deficiency (LAD)

Type I (LAD-1): β2-integrin (CD18) deficiency

  • Pathophysiology: Neutrophils cannot adhere to endothelium or migrate to infection sites
  • Clinical Features:
    • Delayed umbilical cord separation (>3 weeks)
    • Severe recurrent bacterial infections without pus
    • Periodontitis, poor wound healing
    • Marked leukocytosis (>100,000/μL during infection)
  • Lab: Absent CD18/CD11 expression by flow cytometry
  • Treatment: HSCT (severe cases), prophylactic antibiotics

Chédiak-Higashi Syndrome

Genetics: LYST gene mutation (autosomal recessive)

Features:

  • Giant lysosomes in all cells
  • Partial albinism (diluted skin and hair color)
  • Peripheral neuropathy
  • Recurrent pyogenic infections
  • Bleeding tendency (platelet defect)
  • Accelerated phase: hemophagocytic syndrome
  • Treatment: HSCT before accelerated phase
    • Complement Deficiencies ▼
    Deficiency Clinical Manifestations Associated Organisms
    C1, C2, C4 SLE-like autoimmune disease, increased infections Encapsulated bacteria
    C3 Severe recurrent pyogenic infections S. pneumoniae, H. influenzae
    C5-C9 (MAC) Recurrent Neisseria infections N. meningitidis, N. gonorrhoeae
    C1 inhibitor Hereditary angioedema (HAE) N/A (not infectious)
    Properdin, Factor D Recurrent Neisseria infections N. meningitidis
    Decay accelerating factor (DAF) Paroxysmal nocturnal hemoglobinuria (PNH) N/A (RBC lysis)

    Hereditary Angioedema (HAE)

    Pathophysiology: C1 inhibitor deficiency → uncontrolled bradykinin production

    Types:

    • Type I (85%): Low C1 inhibitor levels
    • Type II (15%): Normal levels but dysfunctional
    • Type III: Normal C1-INH (Factor XII mutation)

    Clinical Features:

    • Recurrent episodes of non-pitting, non-pruritic edema
    • Skin, GI tract (abdominal pain), larynx (life-threatening)
    • Triggered by trauma, stress, hormones
    • No urticaria (distinguishes from allergic angioedema)

    Laboratory:

    • Low C4 (screening test)
    • Low C1 inhibitor level/function
    • Normal C3

    Treatment:

    • Acute: C1-INH concentrate, icatibant (bradykinin receptor antagonist), ecallantide (kallikrein inhibitor)
    • Prophylaxis: C1-INH replacement, attenuated androgens (danazol)
    • AVOID: ACE inhibitors (worsen bradykinin accumulation)

    Secondary (Acquired) Immunodeficiencies

    Cause Mechanism Clinical Consequences
    HIV/AIDS CD4⁺ T cell destruction Opportunistic infections, malignancies
    Malnutrition Protein-energy deficiency, micronutrient deficiency Impaired cell-mediated immunity, most common worldwide
    Malignancy Bone marrow infiltration, cytokine dysregulation Especially hematologic malignancies (CLL, multiple myeloma)
    Medications Various mechanisms Corticosteroids, immunosuppressants, chemotherapy
    Asplenia Loss of splenic filtration, impaired antibody response Encapsulated bacteria (pneumococcus, H. flu, meningococcus)
    Diabetes Mellitus Impaired neutrophil function, vascular disease Increased bacterial and fungal infections
    Chronic Kidney Disease Uremic toxins, dialysis Impaired cellular immunity
    Liver Disease Impaired acute phase protein synthesis Complement deficiency, impaired opsonization
    Aging Thymic involution, immunosenescence Decreased vaccine responses, increased infections

    ⚠️ Autoimmune Diseases

    Definition:

    Autoimmunity: Adaptive immune response against self-antigens due to breakdown of self-tolerance

    Autoimmune Disease: Tissue damage or altered physiologic function resulting from autoimmunity

    🔑 Mechanisms of Self-Tolerance

    Central Tolerance

    • T cells (Thymus):
      • Positive selection: MHC restriction
      • Negative selection: Deletion of self-reactive cells
      • AIRE-mediated expression of tissue antigens
    • B cells (Bone Marrow):
      • Receptor editing
      • Clonal deletion
      • Anergy induction

    Peripheral Tolerance

    • Anergy: Lack of costimulation
    • Ignorance: Sequestered antigens
    • Deletion: Activation-induced cell death
    • Regulatory T cells: Active suppression
    • Immune privilege: Eye, testes, brain

    Factors Contributing to Autoimmunity

    Factor Mechanism Examples
    Genetic Predisposition HLA associations, polymorphisms in immune genes HLA-B27 (ankylosing spondylitis), HLA-DR3/DR4 (T1DM)
    Molecular Mimicry Pathogen antigens resemble self-antigens Rheumatic fever (Strep → heart), Guillain-Barré (Campylobacter)
    Epitope Spreading Tissue damage releases new self-antigens Progressive autoimmune diseases
    Bystander Activation Inflammation activates autoreactive cells Post-infectious autoimmunity
    Loss of Immune Privilege Trauma exposes sequestered antigens Sympathetic ophthalmia, post-vasectomy sperm antibodies
    Polyclonal Activation Non-specific lymphocyte activation EBV, HIV infections
    Hormonal Factors Modulation of immune response Female predominance in many autoimmune diseases

    Classification by Predominant Mechanism

    Antibody-Mediated (Type II Hypersensitivity) ▼
    Disease Target Antigen Autoantibody Mechanism/Manifestation
    Graves' Disease TSH receptor Thyroid-stimulating Ig (TSI) Receptor stimulation → hyperthyroidism, exophthalmos
    Myasthenia Gravis Acetylcholine receptor Anti-AChR antibodies Receptor blockade/destruction → muscle weakness, ptosis
    Goodpasture Syndrome Type IV collagen (basement membrane) Anti-GBM antibodies Complement activation → glomerulonephritis, pulmonary hemorrhage
    Pemphigus Vulgaris Desmoglein 3 Anti-desmoglein Loss of keratinocyte adhesion → flaccid blisters
    Autoimmune Hemolytic Anemia RBC surface antigens Anti-RBC antibodies Complement-mediated or splenic destruction of RBCs
    Immune Thrombocytopenia (ITP) Platelet glycoproteins Anti-platelet antibodies Splenic destruction of platelets → bleeding
    Immune Complex-Mediated (Type III Hypersensitivity) ▼

    Systemic Lupus Erythematosus (SLE)

    Pathophysiology: Production of antinuclear antibodies (ANA) → immune complex deposition

    Key Autoantibodies:

    • ANA: Sensitive (95%), not specific
    • Anti-dsDNA: Specific (95%), correlates with disease activity and renal involvement
    • Anti-Smith (anti-Sm): Most specific (99%), not sensitive (30%)
    • Anti-histone: Drug-induced lupus
    • Anti-Ro/SSA & Anti-La/SSB: Sjögren's, neonatal lupus, congenital heart block

    Clinical Manifestations (use SOAP BRAIN MD):

    • Serositis (pleuritis, pericarditis)
    • Oral ulcers (painless)
    • Arthritis (non-erosive)
    • Photosensitivity
    • Blood disorders (cytopenias)
    • Renal disease (glomerulonephritis)
    • ANA positive
    • Immunologic (anti-dsDNA, anti-Sm, antiphospholipid)
    • Neurologic (seizures, psychosis)
    • Malar rash
    • Discoid rash

    Lupus Nephritis Classification (ISN/RPS):

    • Class I: Minimal mesangial
    • Class II: Mesangial proliferative
    • Class III: Focal lupus nephritis (<50% glomeruli)
    • Class IV: Diffuse lupus nephritis (>50% glomeruli) - worst prognosis
    • Class V: Membranous lupus nephritis
    • Class VI: Advanced sclerosing

    Treatment:

    • Mild: NSAIDs, hydroxychloroquine
    • Moderate: Low-dose corticosteroids
    • Severe/Renal: High-dose steroids + cyclophosphamide or mycophenolate
    • Refractory: Belimumab (anti-BLyS), rituximab (anti-CD20)

    Other Immune Complex Diseases

    • Polyarteritis Nodosa: Medium vessel vasculitis, associated with Hepatitis B
    • Post-Streptococcal Glomerulonephritis: Following Group A Strep infection
    • Serum Sickness: Following administration of foreign protein
    T Cell-Mediated (Type IV Hypersensitivity) ▼

    Type 1 Diabetes Mellitus (T1DM)

    Pathophysiology: Autoimmune destruction of pancreatic β-cells

    Genetics: Strong HLA-DR3 and HLA-DR4 association

    Autoantibodies (present years before clinical disease):

    • Glutamic acid decarboxylase (GAD65) - most common
    • Insulin autoantibodies (IAA)
    • Insulinoma-associated protein-2 (IA-2)
    • Zinc transporter 8 (ZnT8)

    Clinical Features:

    • Typically presents in childhood/adolescence
    • Absolute insulin deficiency
    • Prone to ketoacidosis
    • C-peptide low/absent

    Multiple Sclerosis (MS)

    Pathophysiology: Autoimmune demyelination of CNS (oligodendrocytes)

    Clinical Features:

    • Relapsing-remitting pattern (most common initially)
    • Visual disturbances (optic neuritis)
    • Sensory symptoms, weakness
    • Lhermitte's sign (electric sensation down spine with neck flexion)
    • Internuclear ophthalmoplegia (MLF lesion)

    Diagnosis:

    • MRI: Periventricular plaques, dissemination in space and time
    • CSF: Oligoclonal bands, elevated IgG index

    Treatment:

    • Acute relapse: High-dose IV methylprednisolone
    • Disease-modifying: β-interferon, glatiramer, natalizumab, fingolimod, ocrelizumab

    Rheumatoid Arthritis (RA)

    Pathophysiology Chronic inflammation of synovial joints → pannus formation → erosive arthritis
    Genetics HLA-DR4 association
    Autoantibodies
    • Rheumatoid Factor (RF): IgM anti-IgG Fc, 70-80% sensitivity
    • Anti-CCP (cyclic citrullinated peptide): More specific (95%), appears early
    Clinical Features
    • Symmetric polyarthritis of small joints (MCP, PIP, wrists)
    • Morning stiffness >1 hour
    • Swan neck, boutonniere deformities
    • Ulnar deviation
    • Rheumatoid nodules (subcutaneous, extensor surfaces)
    Extra-articular
    • Pulmonary fibrosis, pleural effusion
    • Pericarditis
    • Keratoconjunctivitis sicca
    • Vasculitis
    • Felty syndrome (RA + splenomegaly + neutropenia)
    Treatment
    • First-line: Methotrexate (DMARD)
    • Biologics: Anti-TNF (infliximab, etanercept, adalimumab), anti-IL-6 (tocilizumab), anti-CD20 (rituximab)
    • JAK inhibitors: Tofacitinib
    • Symptomatic: NSAIDs, low-dose prednisone

    Inflammatory Bowel Disease (IBD)

    Feature Crohn's Disease Ulcerative Colitis
    Location Mouth to anus (any part of GI tract) Colon only (rectum → proximal)
    Distribution Skip lesions, transmural Continuous, mucosal/submucosal
    Pathology Granulomas, cobblestone appearance, fissures Crypt abscesses, pseudopolyps, loss of haustra
    Complications Fistulas, strictures, abscesses, malabsorption Toxic megacolon, increased colorectal cancer risk
    Antibodies ASCA (anti-Saccharomyces cerevisiae) p-ANCA (perinuclear anti-neutrophil cytoplasmic)
    Smoking Worsens disease Protective effect

    🧪 Autoantibodies in Clinical Practice

    Autoantibody Target Associated Disease(s) Clinical Significance
    ANA Nuclear antigens SLE, drug-induced lupus, scleroderma Sensitive screening test, not specific
    Anti-dsDNA Double-stranded DNA SLE High specificity, tracks with disease activity
    Anti-Smith (Sm) snRNP core proteins SLE Most specific for SLE
    Anti-histone Histones Drug-induced lupus Hydralazine, procainamide, isoniazid
    Anti-Ro/SSA, Anti-La/SSB RNA-protein complexes Sjögren's syndrome, neonatal lupus Risk of congenital heart block in newborns
    Anti-Scl-70 (topoisomerase I) DNA topoisomerase I Diffuse systemic sclerosis Poor prognosis, lung fibrosis
    Anti-centromere Centromere proteins Limited systemic sclerosis (CREST) Better prognosis
    Anti-Jo-1 Histidyl-tRNA synthetase Polymyositis/dermatomyositis Interstitial lung disease, mechanic's hands
    c-ANCA (PR3) Proteinase-3 Granulomatosis with polyangiitis (Wegener's) Upper/lower respiratory + renal
    p-ANCA (MPO) Myeloperoxidase Microscopic polyangiitis, Churg-Strauss, UC Pauci-immune glomerulonephritis
    Anti-GBM Type IV collagen Goodpasture syndrome Pulmonary hemorrhage + glomerulonephritis
    Rheumatoid Factor IgG Fc region Rheumatoid arthritis 70-80% sensitive, not specific
    Anti-CCP Citrullinated proteins Rheumatoid arthritis 95% specific, predicts erosive disease
    Anti-TSH receptor TSH receptor Graves' disease Stimulating antibody → hyperthyroidism
    Anti-TPO, Anti-Tg Thyroid peroxidase, thyroglobulin Hashimoto's thyroiditis Hypothyroidism
    Anti-AChR Acetylcholine receptor Myasthenia gravis Muscle weakness, ptosis, diplopia
    Anti-MuSK Muscle-specific kinase Myasthenia gravis (seronegative) Bulbar symptoms predominate
    Antiphospholipid antibodies Phospholipids, β2-glycoprotein I Antiphospholipid syndrome Thrombosis, pregnancy loss, false+ VDRL

    ⚡ Hypersensitivity Reactions (Gell-Coombs Classification)

    Definition: Exaggerated or inappropriate immune responses that cause tissue damage

    Summary Overview

    Type Name Mechanism Timing Key Mediators
    Type I Immediate/Anaphylactic IgE-mediated mast cell degranulation Minutes IgE, histamine, leukotrienes
    Type II Antibody-mediated/Cytotoxic IgG/IgM against cell surface antigens Hours IgG, IgM, complement
    Type III Immune Complex Antigen-antibody complex deposition Hours IgG, immune complexes, complement
    Type IV Delayed/Cell-mediated T cell-mediated Days (48-72h) T cells, macrophages, cytokines

    Type I: Immediate Hypersensitivity

    Mechanism

    Step-by-Step Process ▼
    1. Sensitization Phase:
      • First exposure to allergen
      • Th2 response: IL-4, IL-5, IL-13 production
      • B cells class switch to IgE
      • IgE binds to FcεRI receptors on mast cells and basophils
    2. Re-exposure/Effector Phase:
      • Allergen cross-links IgE on mast cells
      • Mast cell degranulation (within minutes)
      • Release of preformed and newly synthesized mediators

    Mediators and Effects

    Mediator Source Effects
    Histamine Preformed granules Vasodilation, vascular permeability, bronchoconstriction, pruritus
    Tryptase Preformed granules Protease activation, marker for anaphylaxis
    Leukotrienes (LTC4, LTD4, LTE4) Newly synthesized Prolonged bronchoconstriction, mucus secretion, vascular permeability
    Prostaglandin D2 Newly synthesized Bronchoconstriction, vasodilation
    Platelet-Activating Factor (PAF) Newly synthesized Platelet aggregation, bronchoconstriction

    Clinical Manifestations

    🌾 Allergic Rhinitis (Hay Fever)

    • Sneezing, rhinorrhea, nasal congestion
    • Itchy eyes, nose, throat
    • Triggered by pollen, dust mites, pet dander
    • Treatment: Antihistamines, nasal steroids, allergen immunotherapy

    🫁 Asthma

    • Bronchial hyperreactivity, reversible airflow obstruction
    • Wheezing, dyspnea, cough, chest tightness
    • Early phase (minutes) + late phase (4-8 hours)
    • Treatment: β-agonists, inhaled steroids, leukotriene inhibitors, anti-IgE (omalizumab)

    🍽️ Food Allergy

    • Common: peanuts, tree nuts, shellfish, eggs, milk, soy
    • Oral itching, urticaria, GI symptoms
    • Can progress to anaphylaxis
    • Diagnosis: Skin prick test, specific IgE, oral food challenge

    🐝 Atopic Dermatitis (Eczema)

    • Chronic pruritic skin inflammation
    • Flexural distribution, lichenification
    • Elevated IgE, eosinophilia
    • Treatment: Emollients, topical steroids, calcineurin inhibitors, dupilumab (anti-IL-4R)

    ⚠️ Anaphylaxis

    Definition:

    Severe, life-threatening systemic hypersensitivity reaction

    Common Triggers:

    • Foods (peanuts, tree nuts, shellfish)
    • Medications (β-lactams, NSAIDs)
    • Insect stings (Hymenoptera venom)
    • Latex
    • Idiopathic

    Clinical Criteria (≥1 of following):

    1. Acute onset (minutes to hours) involving skin/mucosa + respiratory compromise OR hypotension
    2. Two or more of: skin/mucosa, respiratory, hypotension, GI symptoms after likely allergen
    3. Hypotension after known allergen exposure

    Signs and Symptoms:

    • Skin: Urticaria, angioedema, flushing, pruritus (most common, 90%)
    • Respiratory: Dyspnea, wheeze, stridor, hypoxia (70%)
    • Cardiovascular: Hypotension, tachycardia, syncope, shock (45%)
    • GI: Nausea, vomiting, diarrhea, cramping (45%)
    • CNS: Altered mental status, sense of impending doom

    Emergency Management:

    1. Epinephrine 0.3-0.5 mg IM (1:1000) into anterolateral thigh - FIRST LINE
      • Repeat q5-15 min if needed
      • Most important intervention
    2. Remove trigger if possible
    3. Place patient supine with legs elevated (if not vomiting)
    4. Oxygen supplementation
    5. IV fluids for hypotension (1-2 L bolus)
    6. H1 antihistamine (diphenhydramine 25-50 mg IV)
    7. H2 antihistamine (ranitidine 50 mg IV)
    8. Corticosteroids (methylprednisolone 125 mg IV) - prevent biphasic reaction
    9. β2-agonists (albuterol) for bronchospasm
    10. Glucagon (for patients on β-blockers)

    Post-Anaphylaxis Management:

    • Observe 4-8 hours (biphasic reactions occur in 5-20%)
    • Discharge with epinephrine auto-injector (EpiPen)
    • Medical alert bracelet
    • Referral to allergist for testing and immunotherapy

    Type II: Antibody-Mediated Cytotoxic Reactions

    Mechanisms of Tissue Damage:

    1. Opsonization and phagocytosis: IgG coating → Fc receptor binding → phagocytosis
    2. Complement-mediated lysis: Antibody binding → classical pathway → MAC formation
    3. ADCC: NK cells bind antibody-coated targets via CD16 (FcγRIII)
    4. Antibody-mediated cellular dysfunction: Block or stimulate receptors

    Clinical Examples

    Transfusion Reactions ▼

    ABO Incompatibility - Acute Hemolytic Transfusion Reaction

    Most dangerous transfusion reaction

    Pathophysiology: Preformed IgM antibodies against ABO antigens → immediate intravascular hemolysis

    Clinical Features:

    • Onset within minutes of transfusion
    • Fever, chills, back pain, chest pain
    • Hemoglobinuria (red/brown urine)
    • Hypotension, DIC
    • Acute renal failure

    Management:

    1. Stop transfusion immediately
    2. Maintain renal perfusion (IV fluids, diuretics)
    3. Monitor for DIC
    4. Supportive care

    Rh Incompatibility - Hemolytic Disease of the Newborn

    Scenario: Rh-negative mother, Rh-positive fetus

    Pathophysiology:

    1. First pregnancy: Mother sensitized during delivery (fetal RBCs enter maternal circulation)
    2. Mother produces anti-Rh IgG antibodies
    3. Subsequent pregnancies: Maternal IgG crosses placenta → fetal RBC hemolysis

    Clinical Features:

    • Jaundice, kernicterus
    • Anemia, hepatosplenomegaly
    • Hydrops fetalis (severe cases)

    Prevention:

    • RhoGAM (anti-D immunoglobulin)
    • Given to Rh-negative mothers at 28 weeks and within 72 hours of delivery
    • Binds fetal Rh+ RBCs → prevents maternal sensitization
    Drug-Induced Immune Cytopenias ▼

    Drug-Induced Hemolytic Anemia

    • Penicillin type: Drug binds RBC → antibody against drug-RBC complex
    • Quinidine type: Drug-antibody complex binds RBC (innocent bystander)
    • Methyldopa type: True autoantibodies against RBC antigens

    Drug-Induced Thrombocytopenia

    • Common drugs: Heparin, quinine, sulfonamides, vancomycin
    • Antibodies against drug-platelet complexes
    • Thrombocytopenia, bleeding

    Heparin-Induced Thrombocytopenia (HIT)

    Paradoxical: Thrombocytopenia + Thrombosis

    Pathophysiology: Antibodies against heparin-PF4 complex → platelet activation → thrombosis

    Clinical: Thrombocytopenia (typically >50% drop), arterial/venous thrombosis

    Diagnosis: 4T score, anti-PF4 antibodies, serotonin release assay

    Management:

    • Stop ALL heparin (including flushes)
    • Alternative anticoagulation: argatroban, fondaparinux, DOACs
    • AVOID warfarin alone (risk of limb gangrene)
    • AVOID platelet transfusions (worsen thrombosis)

    Type III: Immune Complex-Mediated Reactions

    Pathophysiology:

    1. Formation of antigen-antibody complexes (IgG or IgM)
    2. Complexes deposit in tissues (blood vessels, glomeruli, joints, skin)
    3. Complement activation → C3a, C5a (anaphylatoxins)
    4. Neutrophil recruitment and activation
    5. Release of lysosomal enzymes and ROS → tissue damage

    Factors affecting deposition: Size of complexes, charge, site of formation, hemodynamics

    Arthus Reaction

    Local Type III reaction

    Mechanism: Repeated injection of antigen → local immune complex formation and deposition

    Clinical: Local edema, erythema, necrosis at injection site (3-8 hours)

    Example: Repeated vaccine injections at same site

    Serum Sickness

    Definition Systemic Type III reaction from foreign protein or drug exposure
    Causes
    • Antitoxins, antivenoms (horse serum)
    • Monoclonal antibodies (rituximab, infliximab)
    • Drugs: β-lactams, sulfonamides, allopurinol
    Timing 7-21 days after exposure (time for antibody formation)
    Clinical Features
    • Fever, malaise
    • Urticaria, angioedema
    • Arthralgias, arthritis
    • Lymphadenopathy
    • Glomerulonephritis (less common)
    Laboratory
    • ↓ C3, C4 (complement consumption)
    • ↑ ESR, CRP
    • Circulating immune complexes
    Treatment
    • Self-limited (resolves in 1-2 weeks)
    • Discontinue offending agent
    • NSAIDs, antihistamines for symptoms
    • Corticosteroids for severe cases

    Type IV: Delayed-Type Hypersensitivity

    Characteristics:

    • T cell-mediated (no antibodies involved)
    • Delayed onset: 48-72 hours
    • Does not transfer with serum (transfers with T cells)
    • Requires prior sensitization

    Subtypes of Type IV Reactions

    Subtype Effector Cells Key Cytokines Examples
    IVa Th1 cells, macrophages IFN-γ, IL-2 Tuberculin reaction, contact dermatitis
    IVb Th2 cells, eosinophils IL-4, IL-5, IL-13 Chronic asthma, chronic allergic rhinitis
    IVc CD8+ CTLs Perforin, granzyme Contact dermatitis, viral rejection
    IVd Neutrophils IL-8, CXCL8 Pustular drug eruptions

    Clinical Examples

    Tuberculin (Mantoux) Test

    • Intradermal injection of PPD (purified protein derivative)
    • Prior TB exposure/BCG → sensitized T cells
    • T cells recognize antigen → local inflammation
    • Read at 48-72 hours (induration, not erythema)
    • Interpretation depends on risk factors

    Contact Dermatitis

    • Poison ivy/oak (urushiol)
    • Nickel, cosmetics, fragrances
    • Latex
    • Localized eczematous reaction
    • Treatment: Avoid allergen, topical steroids

    Granulomatous Inflammation

    • Persistent antigen/pathogen
    • Macrophages form epithelioid cells
    • Multinucleated giant cells (Langhans)
    • TB, leprosy, sarcoidosis, Crohn's

    Transplant Rejection

    • Hyperacute: Minutes (preformed antibodies)
    • Acute: Weeks-months (T cell-mediated)
    • Chronic: Months-years (antibody + T cells)

    💉 Vaccines and Immunization

    Definition:

    Vaccination: Administration of antigenic material to stimulate adaptive immunity and establish immunological memory

    Goal: Provide protection against future infection without causing disease

    Types of Vaccines

    Type Description Advantages Disadvantages Examples
    Live Attenuated Weakened live pathogen, can replicate but doesn't cause disease
    • Strong, long-lasting immunity
    • Cellular + humoral response
    • Often single dose
    • Mimics natural infection
    • Risk of reversion to virulence
    • Contraindicated in immunocompromised
    • Requires refrigeration
    • Can cause mild disease
    		 MMR, Varicella, Rotavirus, Yellow fever, Oral polio (OPV), BCG, Intranasal influenza
    Inactivated (Killed) Killed pathogen, cannot replicate
    • Safe in immunocompromised
    • No risk of reversion
    • More stable storage
    • Weaker immune response
    • Requires multiple doses/boosters
    • Mainly humoral immunity
    		 Injectable polio (IPV), Hepatitis A, Rabies, Injectable influenza
    Subunit/Protein Specific antigenic proteins
    • Very safe
    • Well-tolerated
    • Can focus on protective antigens
    • Requires adjuvants
    • Multiple doses needed
    • Expensive to produce
    		 Hepatitis B, HPV, Acellular pertussis, Meningococcal B
    Toxoid Inactivated bacterial toxin
    • Safe
    • Effective against toxin-mediated diseases
    • Requires boosters
    • Only protects against toxin
    		 Tetanus, Diphtheria
    Conjugate Polysaccharide antigen linked to protein carrier
    • T-cell help → better immunity
    • Effective in children <2 years
    • Immunologic memory
    • Complex manufacturing
    • Expensive
    		 Hib, Pneumococcal (PCV13), Meningococcal (MenACWY)
    Polysaccharide Purified bacterial capsular polysaccharides
    • Safe
    • T-independent response
    • Poor in children <2 years
    • No memory formation
    • Repeated doses → hyporesponsiveness
    		 Pneumococcal (PPSV23), Meningococcal (MPSV4), Typhoid (Vi)
    mRNA Synthetic mRNA encoding antigen
    • Rapid development
    • No live virus
    • Strong immune response
    • Easily modifiable
    • Requires ultra-cold storage
    • New technology
    • Requires lipid nanoparticle delivery
    		 COVID-19 (Pfizer-BioNTech, Moderna)
    Viral Vector Uses harmless virus to deliver antigen genes
    • Strong cellular immunity
    • Single dose possible
    • Standard refrigeration
    • Pre-existing vector immunity may reduce efficacy
    • Complex manufacturing
    		 COVID-19 (J&J, AstraZeneca), Ebola (Ervebo)

    Vaccine Adjuvants

    Purpose: Enhance and prolong immune response to antigens

    Adjuvant Mechanism Used In
    Aluminum salts (Alum) Depot effect, inflammasome activation, Th2 response Most common: DTaP, Hepatitis A/B, HPV
    MF59 Squalene-based oil-in-water emulsion Influenza vaccines (elderly)
    AS04 Alum + MPL (TLR4 agonist) HPV (Cervarix), Hepatitis B (Fendrix)
    CpG oligonucleotides TLR9 agonist, strong Th1 response Hepatitis B (Heplisav-B)

    🗓️ Vaccine Schedules and Recommendations

    Childhood Immunization Schedule (CDC - Key Points):

    • Birth: Hepatitis B #1
    • 2, 4, 6 months: DTaP, Hib, IPV, PCV13, Rotavirus
    • 6 months - annually: Influenza
    • 12-15 months: MMR #1, Varicella #1, Hepatitis A #1, PCV13 #4
    • 15-18 months: DTaP #4
    • 4-6 years: DTaP #5, IPV #4, MMR #2, Varicella #2
    • 11-12 years: Tdap, HPV series, Meningococcal conjugate (MenACWY)
    • 16 years: Meningococcal booster, consider MenB

    Adult Immunization Highlights

    Vaccine Recommendation Special Populations
    Influenza Annual for all adults High-dose or adjuvanted for ≥65 years
    Tdap/Td Tdap once, then Td every 10 years Tdap during each pregnancy (27-36 weeks)
    Pneumococcal PCV15 or PCV20 for ≥65 years or high-risk Asplenia, immunocompromised, CSF leak
    Zoster (Shingles) Shingrix (2 doses) for ≥50 years Recommended even if prior zoster or Zostavax
    HPV Catch-up through age 26 if not previously vaccinated Can give up to age 45 (shared decision)
    MMR If born ≥1957 without evidence of immunity Healthcare workers, international travelers
    Hepatitis B Universal recommendation for adults 19-59 Risk factors at any age
    COVID-19 Updated vaccine annually Additional doses for immunocompromised

    ⚠️ Contraindications to Vaccination

    Absolute Contraindications:

    • All vaccines: Severe allergic reaction (anaphylaxis) to vaccine component or prior dose
    • Live vaccines:
      • Pregnancy
      • Severe immunodeficiency (SCID, HIV with CD4 <200, high-dose immunosuppression)
    • DTaP: Encephalopathy within 7 days of prior dose

    Precautions (Not Contraindications):

    • Moderate or severe acute illness (defer until improvement)
    • History of Guillain-Barré syndrome (consider for influenza)
    • Recent immunoglobulin administration (for live vaccines - wait 3-11 months)

    NOT Contraindications (Common Misconceptions):

    • Mild illness or low-grade fever
    • Current antibiotic therapy
    • Prematurity (use chronological age for vaccination)
    • Egg allergy (for most vaccines, including influenza)
    • Breastfeeding
    • Family history of adverse reactions

    🎯 Herd Immunity and Vaccine Efficacy

    Herd Immunity

    Definition: Indirect protection of unvaccinated individuals when a sufficient proportion of the population is immune

    Herd Immunity Threshold: HIT = 1 - (1/R₀)

    Where R₀ = basic reproduction number (average number of people infected by one case)

    Examples of Herd Immunity Thresholds:

    • Measles (R₀ = 12-18): Requires 92-95% vaccination coverage
    • Pertussis (R₀ = 12-17): Requires 92-94% vaccination coverage
    • Polio (R₀ = 5-7): Requires 80-86% vaccination coverage
    • Influenza (R₀ = 2-3): Requires 50-67% vaccination coverage

    Vaccine Effectiveness Measures

    Term Definition Context
    Vaccine Efficacy Protection under ideal conditions (clinical trials) Formula: VE = (1 - RR) × 100%
    Vaccine Effectiveness Protection in real-world conditions Usually lower than efficacy
    Seroconversion Rate % developing protective antibody titers Immunogenicity measure
    Duration of Protection Time immunity lasts Determines booster schedule

    💊 Special Vaccination Scenarios

    Immunocompromised Patients

    General Principles:

    • Avoid live vaccines in severely immunocompromised
    • Inactivated vaccines are safe but may be less effective
    • Consider checking antibody titers post-vaccination
    • May need additional doses or higher doses
    • Vaccinate household contacts with appropriate vaccines

    HIV Patients:

    • CD4 >200: Can receive most vaccines including MMR, Varicella
    • CD4 <200: Avoid all live vaccines
    • Give vaccines when CD4 highest or on ART
    • Additional pneumococcal, meningococcal vaccines recommended

    Organ Transplant Recipients:

    • Complete all appropriate vaccines ≥4 weeks before transplant
    • After transplant: avoid live vaccines indefinitely
    • May restart inactivated vaccines ≥3-6 months post-transplant

    Asplenia/Hyposplenia:

    • High risk for encapsulated bacteria (pneumococcus, Hib, meningococcus)
    • Essential vaccines: PCV13/PCV20, PPSV23, Hib, MenACWY, MenB
    • Ideally vaccinate ≥2 weeks before splenectomy
    • Lifelong antibiotic prophylaxis (consider penicillin or amoxicillin)

    Pregnancy

    Recommended During Pregnancy:

    • Tdap: Every pregnancy, preferably 27-36 weeks (protects newborn)
    • Influenza: Any trimester during flu season (inactivated only)
    • COVID-19: Recommended during any trimester

    Contraindicated During Pregnancy (Live Vaccines):

    • MMR
    • Varicella
    • Live attenuated influenza (LAIV)
    • Yellow fever (unless high-risk travel)

    Note: Inadvertent vaccination during pregnancy with live vaccines is not an indication for pregnancy termination; counsel and monitor

    🎯 Cancer Immunotherapy

    Concept:

    Harness the immune system to recognize and destroy cancer cells

    Cancers evade immunity through:

    • Loss of tumor antigens
    • Downregulation of MHC-I
    • Expression of immune checkpoint ligands (PD-L1)
    • Immunosuppressive tumor microenvironment

    Types of Cancer Immunotherapy

    Immune Checkpoint Inhibitors ▼

    Mechanism:

    Block inhibitory signals that normally prevent T cell activation, unleashing anti-tumor immunity

    Target Agents Mechanism Indications
    PD-1 (Programmed Death-1) Pembrolizumab, Nivolumab, Cemiplimab Block PD-1 on T cells → prevents interaction with PD-L1/L2 → T cell activation Melanoma, NSCLC, RCC, Hodgkin lymphoma, MSI-high tumors, many others
    PD-L1 (Programmed Death-Ligand 1) Atezolizumab, Durvalumab, Avelumab Block PD-L1 on tumor/immune cells → prevents interaction with PD-1 Urothelial carcinoma, NSCLC, triple-negative breast cancer
    CTLA-4 (Cytotoxic T-Lymphocyte Antigen-4) Ipilimumab, Tremelimumab Block CTLA-4 on T cells → prevents binding to CD80/86 → enhanced T cell activation Melanoma, RCC (often combined with anti-PD-1)

    Immune-Related Adverse Events (irAEs):

    Result from excessive immune activation affecting normal tissues

    • Dermatologic: Rash, pruritus, vitiligo (most common, usually mild)
    • GI: Colitis, diarrhea (can be severe with anti-CTLA-4)
    • Hepatic: Hepatitis (elevated transaminases)
    • Endocrine: Thyroiditis, hypophysitis, adrenal insufficiency, diabetes
    • Pulmonary: Pneumonitis (potentially fatal)
    • Cardiac: Myocarditis (rare but serious)
    • Neurologic: Encephalitis, neuropathy, myasthenia gravis
    • Rheumatologic: Arthritis, myositis

    Management:

    • Grade 1-2 (Mild-Moderate): Continue therapy with monitoring, symptomatic treatment
    • Grade 3-4 (Severe-Life-threatening):
      • Hold immunotherapy
      • High-dose corticosteroids (prednisone 1-2 mg/kg/day)
      • If refractory: infliximab, mycophenolate
      • Permanently discontinue for severe events
    CAR-T Cell Therapy ▼

    Chimeric Antigen Receptor T Cell Therapy

    Process:

    1. Collection: Patient's T cells collected via leukapheresis
    2. Engineering: T cells genetically modified to express CAR (chimeric antigen receptor)
    3. Expansion: Modified T cells cultured and expanded ex vivo
    4. Conditioning: Patient receives lymphodepleting chemotherapy
    5. Infusion: CAR-T cells infused back into patient
    6. Expansion in vivo: CAR-T cells proliferate and attack cancer cells

    FDA-Approved CAR-T Therapies:

    Product Target Indication
    Tisagenlecleucel (Kymriah) CD19 B-cell ALL (pediatric/young adult), B-cell lymphoma
    Axicabtagene ciloleucel (Yescarta) CD19 B-cell lymphoma
    Brexucabtagene autoleucel (Tecartus) CD19 Mantle cell lymphoma, B-cell ALL
    Lisocabtagene maraleucel (Breyanzi) CD19 B-cell lymphoma
    Idecabtagene vicleucel (Abecma) BCMA Multiple myeloma
    Ciltacabtagene autoleucel (Carvykti) BCMA Multiple myeloma

    Major Toxicities:

    • Cytokine Release Syndrome (CRS):
      • Massive T cell activation → cytokine storm (IL-6, IFN-γ, TNF-α)
      • Fever, hypotension, hypoxia, organ dysfunction
      • Onset: typically 1-14 days post-infusion
      • Treatment:
        • Supportive care, antipyretics
        • Tocilizumab (anti-IL-6R antibody) - first-line
        • Corticosteroids if refractory
    • Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS):
      • Confusion, encephalopathy, aphasia, seizures, cerebral edema
      • Can occur with or after CRS
      • Treatment: Corticosteroids, supportive care, seizure management
    • B-cell Aplasia: Expected on-target, off-tumor effect for CD19 CAR-T
      • Hypogammaglobulinemia
      • Requires IVIG replacement
    Therapeutic Antibodies ▼

    Monoclonal Antibodies in Cancer

    Antibody Target Mechanism Indications
    Rituximab CD20 ADCC, complement-mediated lysis, direct apoptosis B-cell lymphomas, CLL, autoimmune diseases
    Trastuzumab HER2/neu Block HER2 signaling, ADCC HER2+ breast cancer, gastric cancer
    Cetuximab EGFR Block EGFR signaling, ADCC Colorectal cancer, head and neck cancer
    Bevacizumab VEGF-A Inhibit angiogenesis Colorectal, lung, kidney, glioblastoma
    Alemtuzumab CD52 Complement-mediated lysis, ADCC CLL, T-cell lymphoma

    Bispecific Antibodies:

    Engage two different antigens simultaneously

    • Blinatumomab: CD3 (T cells) × CD19 (B cells)
      • Brings T cells into proximity with B-cell malignancies
      • Indication: B-cell ALL
    • Multiple others in development

    Antibody-Drug Conjugates (ADCs):

    Monoclonal antibody linked to cytotoxic drug - targeted chemotherapy delivery

    • Trastuzumab emtansine (T-DM1): HER2 × emtansine (microtubule inhibitor) - HER2+ breast cancer
    • Brentuximab vedotin: CD30 × MMAE - Hodgkin lymphoma, ALCL
    • Gemtuzumab ozogamicin: CD33 × calicheamicin - AML
    Cancer Vaccines ▼

    Types:

    Preventive Cancer Vaccines

    • HPV vaccine: Prevents cervical, anal, oropharyngeal cancers
    • Hepatitis B vaccine: Prevents hepatocellular carcinoma

    Therapeutic Cancer Vaccines

    • Sipuleucel-T (Provenge):
      • Autologous dendritic cell vaccine
      • Loaded with prostatic acid phosphatase (PAP)
      • FDA-approved for metastatic castration-resistant prostate cancer
    • BCG: Intravesical therapy for bladder cancer (immunostimulant)
    • Talimogene laherparepvec (T-VEC): Oncolytic virus for melanoma
    Cytokine Therapy ▼
    Cytokine Mechanism Indications Toxicities
    IL-2 (Aldesleukin) T cell and NK cell activation and proliferation Metastatic melanoma, renal cell carcinoma Capillary leak syndrome, hypotension, organ dysfunction
    IFN-α Antiproliferative, immunomodulatory, antiangiogenic Melanoma, CML, renal cell carcinoma, hepatitis B/C Flu-like symptoms, depression, cytopenias
    GM-CSF Stimulates neutrophil/macrophage production Adjuvant to chemotherapy, stem cell mobilization Bone pain, flu-like symptoms

    🌿 Allergen Immunotherapy

    Concept:

    Gradual exposure to increasing doses of allergen to induce tolerance

    Mechanisms:

    • Shift from Th2 to Th1/Treg response
    • Increase in IgG4 (blocking antibodies)
    • Decrease in IgE over time
    • Reduced mast cell and basophil degranulation

    Types of Allergen Immunotherapy

    Subcutaneous Immunotherapy (SCIT)

    • Traditional method: "Allergy shots"
    • Build-up phase: Weekly injections with increasing doses (3-6 months)
    • Maintenance phase: Monthly injections (3-5 years)
    • Indications: Allergic rhinitis, allergic asthma, venom allergy
    • Efficacy: 80-90% improvement in symptoms
    • Risk: Anaphylaxis (requires 30-minute observation)

    Sublingual Immunotherapy (SLIT)

    • Tablet/liquid under tongue
    • Administration: Daily at home
    • Duration: Typically 3-5 years
    • Available for: Grass pollen, ragweed, dust mites
    • Advantages: Safer (lower anaphylaxis risk), convenient
    • Disadvantages: Less effective than SCIT, not for venom

    Oral Immunotherapy (OIT) for Food Allergies

    Emerging therapy for food allergies (peanut, egg, milk)

    • Gradual dose escalation of food allergen
    • Palforzia: FDA-approved peanut OIT for children 4-17 years
    • Goal: Desensitization (protection while taking daily) vs. tolerance (lasting protection)
    • Risks: Allergic reactions during dose escalation, requires ongoing daily dosing

    🔬 Immunosuppressive Therapy

    Indications:

    • Autoimmune diseases
    • Transplant rejection prevention
    • Graft-versus-host disease
    • Severe allergic/inflammatory conditions

    Classes of Immunosuppressive Agents

    Class Agents Mechanism Key Toxicities
    Corticosteroids Prednisone, methylprednisolone, dexamethasone Inhibit NF-κB, decrease cytokine production, lymphocyte apoptosis Hyperglycemia, osteoporosis, infections, cushingoid features
    Calcineurin Inhibitors Cyclosporine, tacrolimus Inhibit calcineurin → block IL-2 production → T cell suppression Nephrotoxicity, hypertension, neurotoxicity, gingival hyperplasia (cyclosporine)
    Antimetabolites Azathioprine, mycophenolate, methotrexate Inhibit nucleotide synthesis → impair lymphocyte proliferation Cytopenias, hepatotoxicity, GI toxicity, infections
    mTOR Inhibitors Sirolimus, everolimus Inhibit mTOR → block IL-2 signaling → T cell inhibition Hyperlipidemia, impaired wound healing, pneumonitis
    Biologics - Anti-TNF Infliximab, adalimumab, etanercept Neutralize TNF-α Infections (especially TB reactivation), lymphoma risk
    Biologics - Anti-IL-6 Tocilizumab, sarilumab Block IL-6 receptor Infections, elevated liver enzymes, cytopenias
    Biologics - Anti-CD20 Rituximab, ocrelizumab Deplete B cells Infusion reactions, PML risk, hypogammaglobulinemia
    JAK Inhibitors Tofacitinib, baricitinib Inhibit JAK-STAT signaling pathway Infections, thrombosis, cytopenias
    Costimulation Blocker Abatacept, belatacept Block CD28-CD80/86 interaction → prevent T cell activation Infections, post-transplant lymphoproliferative disorder

    🩺 Laboratory Evaluation of Immune Function

    Initial Screening Tests

    Test What It Evaluates Normal Range Clinical Interpretation
    CBC with Differential Quantitative immune cells WBC: 4,500-11,000/μL
    Lymphocytes: 20-40%
    Neutrophils: 50-70%     		Lymphopenia, neutropenia, eosinophilia
    Immunoglobulins (Quantitative) Humoral immunity IgG: 700-1600 mg/dL
    IgA: 70-400 mg/dL
    IgM: 40-230 mg/dL
    IgE: <100 IU/mL     		Hypogammaglobulinemia, elevated IgE in atopy
    Vaccine Titers Antibody response to antigens Protective levels vary by vaccine Assess functional humoral immunity
    CH50 Total complement activity 30-75 U/mL Screens classical + terminal pathway
    AH50 Alternative pathway complement Laboratory-specific Screens alternative pathway

    Advanced/Specialized Tests

    Lymphocyte Subset Analysis (Flow Cytometry) ▼
    Marker Cell Type Normal % of Lymphocytes Absolute Count (cells/μL)
    CD3+ Total T cells 60-80% 1000-2200
    CD3+ CD4+ Helper T cells 35-55% 500-1200
    CD3+ CD8+ Cytotoxic T cells 20-35% 300-900
    CD4/CD8 Ratio T cell balance 1.0-2.5 N/A
    CD19+ or CD20+ B cells 5-20% 100-500
    CD3- CD56+ NK cells 5-15% 100-400
    Functional Immune Assays ▼
    • Lymphocyte Proliferation Assays:
      • Mitogen stimulation (PHA, ConA, PWM)
      • Antigen-specific responses
      • Assesses T cell function
    • NK Cell Cytotoxicity:
      • Measures NK cell killing ability
      • 51-Chromium release assay or flow-based
    • Neutrophil Function Tests:
      • Oxidative burst (DHR flow cytometry)
      • Nitroblue tetrazolium (NBT) test
      • Chemotaxis assays
    • Specific Antibody Responses:
      • Pre- and post-vaccination titers
      • Polysaccharide antigens (pneumococcal)
      • Protein antigens (tetanus, diphtheria)
    Allergy Testing ▼

    Skin Prick Testing (SPT)

    • Gold standard for IgE-mediated allergies
    • Detects immediate hypersensitivity
    • Results in 15-20 minutes
    • Positive: wheal ≥3mm larger than negative control
    • Must discontinue antihistamines 3-7 days prior

    Intradermal Testing

    • More sensitive than SPT but less specific
    • Used for drug allergy, venom allergy evaluation
    • Higher risk of systemic reactions

    Specific IgE Testing (ImmunoCAP)

    • Blood test measuring allergen-specific IgE
    • Not affected by antihistamines
    • Useful when skin testing not possible
    • Class 0-6 scale or kU/L quantification

    Patch Testing

    • For contact dermatitis (Type IV hypersensitivity)
    • Allergens applied to back for 48 hours
    • Read at 48 and 96 hours

    Basophil Activation Test (BAT)

    • Flow cytometry-based
    • Measures basophil activation (CD63, CD203c)
    • Useful for drug allergy diagnosis

    🦠 Infection Patterns in Immunodeficiency

    Immune Defect Common Pathogens Infection Sites Clinical Clues
    Antibody Deficiency Encapsulated bacteria:
    - S. pneumoniae
    - H. influenzae
    - S. aureus
    - Enteroviruses
    - Giardia     		Sinopulmonary, GI tract Recurrent otitis, sinusitis, pneumonia, bronchiectasis, chronic diarrhea
    T Cell Deficiency Opportunistic:
    - Pneumocystis jirovecii
    - Fungi (Candida, Aspergillus)
    - Viruses (CMV, EBV, HSV)
    - Mycobacteria
    - Parasites (Toxoplasma)     		Disseminated, systemic Chronic mucocutaneous candidiasis, failure to thrive, severe viral infections, disseminated BCG
    Combined B and T Cell Deficiency All of the above Multiple sites Severe infections from infancy, failure to thrive, chronic diarrhea, GVHD from transfusions
    Phagocyte Defects Catalase-positive bacteria:
    - S. aureus
    - Serratia
    - Burkholderia
    - Nocardia
    Fungi:
    - Aspergillus     		Skin, lungs, liver, lymph nodes Deep abscesses, poor wound healing, granulomas, recurrent abscesses without pus (LAD)
    Complement Deficiency C5-C9 (MAC):
    - Neisseria (meningitis, gonorrhea)
    C3:
    - Encapsulated bacteria
    Early components:
    - Pyogenic bacteria + autoimmunity     		Meninges, bloodstream Recurrent or severe Neisseria infections, family history of meningococcal disease
    Asplenia Encapsulated bacteria:
    - S. pneumoniae
    - H. influenzae
    - N. meningitidis
    - Babesia
    - Malaria     		Bloodstream (sepsis) Overwhelming post-splenectomy infection (OPSI), rapid progression, high mortality

    📋 Clinical Pearls and Key Concepts

    🎯 Immunization Key Points

    • Live vaccines contraindicated in pregnancy and severe immunodeficiency
    • Asplenic patients need encapsulated bacteria vaccines
    • Vaccine efficacy may be reduced in immunocompromised
    • Check titers post-vaccination in immunodeficiency
    • Most vaccine side effects are minor and temporary

    ⚠️ Red Flags for Immunodeficiency

    • ≥8 ear infections/year
    • ≥2 serious sinus infections/year
    • ≥2 pneumonias/year
    • Failure to thrive in infancy
    • Opportunistic infections
    • Family history of immunodeficiency or early deaths

    💊 Immunotherapy Considerations

    • Checkpoint inhibitors can cause immune-related adverse events
    • CAR-T therapy requires specialized centers
    • Always monitor for infections with immunosuppression
    • Consider PJP and fungal prophylaxis in high-risk patients
    • Screen for latent TB before starting biologics

    🔬 Diagnostic Approach

    • Start with screening tests: CBC, Ig levels, CH50
    • Pattern of infections guides further testing
    • Flow cytometry for lymphocyte subsets if T/B cell defect suspected
    • Functional assays confirm specific defects
    • Genetic testing increasingly available

    🌟 Autoimmunity Insights

    • Autoantibodies may precede clinical disease by years
    • Female predominance in most autoimmune diseases
    • Environmental triggers often necessary
    • Overlap syndromes are common
    • Biologics revolutionizing treatment

    🎓 Teaching Points

    • Innate = Fast, non-specific, no memory
    • Adaptive = Slow, specific, memory formation
    • T cells need MHC presentation
    • B cells can recognize native antigen
    • Memory response is faster and stronger

    📚 Evidence-Based Guidelines References

    This tool synthesizes information from:

    • International Union of Immunological Societies (IUIS) - Primary Immunodeficiency Classification
    • American Academy of Allergy, Asthma & Immunology (AAAAI) - Practice Parameters
    • European Society for Immunodeficiencies (ESID) - Diagnostic Criteria
    • CDC/ACIP - Vaccination Guidelines
    • American College of Rheumatology (ACR) - Autoimmune Disease Guidelines
    • National Comprehensive Cancer Network (NCCN) - Immunotherapy Guidelines
    • Abbas, Lichtman & Pillai - Basic Immunology and Cellular and Molecular Immunology
    • Harrison's Principles of Internal Medicine - 21st Edition
    • UpToDate - Current Clinical Information (2025)

    Note: This educational tool is based on current evidence and guidelines as of 2025. Clinical decisions should always consider individual patient factors and the most recent medical literature.

    Comprehensive Immunity Guide (by Didactic Med)

    Evidence-Based Medical Education | For Healthcare Professionals

    References: Based on current immunology guidelines including IUIS Classification, UpToDate, Harrison's Principles of Internal Medicine, and Abbas-Lichtman-Pillai Basic Immunology.

    Last Updated: 2025 | This tool is for educational purposes and should not replace clinical judgment